K2M, Inc. is a Public Company (NASDAQ-KTWO) focused on the research, development, and commercialization of innovative solutions for the treatment of complex spinal pathologies and minimally invasive procedures. The company is recognized as a global leader in providing unique technologies for the treatment of deformity, degenerative, trauma, and tumor spinal patients. K2M’s product development pipeline includes: spinal
stabilization systems, minimally invasive systems, biologics, and other advancing technologies, such as motion preservation, annular repair, and nucleus replacement.